# Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome

> **NCT00527566** · PHASE1,PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 10 (actual)

## Conditions studied

- Churg Strauss Syndrome

## Interventions

- **BIOLOGICAL:** Mepolizumab

## Key facts

- **NCT ID:** NCT00527566
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527566, "Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00527566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*